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Flavin-containing monooxygenases (FMOs) are, after cytochromes
P450, the most important monooxygenase system in humans and
are involved in xenobiotics metabolism and variability in drug
response. The x-ray structure of a soluble prokaryotic FMO from
Methylophaga sp. strain SK1 has been solved at 2.6-Å resolution
and is now the protein of known structure with the highest
sequence similarity to human FMOs. The structure possesses a
two-domain architecture, with both FAD and NADP well defined
by the electron density maps. Biochemical analysis shows that the
prokaryotic enzyme shares many functional properties with mam-
malian FMOs, including substrate specificity and the ability to
stabilize the hydroperoxyflavin intermediate that is crucial in
substrate oxygenation. On the basis of their location in the struc-
ture, the nicotinamide ring and the adjacent ribose of NADP turn
out to be an integral part of the catalytic site being actively
engaged in the stabilization of the oxygenating intermediate. This
feature suggests that NADP(H) has a moonlighting role, in that it
adopts two binding modes that allow it to function in both flavin
reduction and oxygen reactivity modulation, respectively. We
hypothesize that a relative domain rotation is needed to bring
NADP(H) to these distinct positions inside the active site. Localiza-
tion of mutations in human FMO3 that are known to cause
trimethylaminuria (fish-odor syndrome) in the elucidated FMO
structure provides a structural explanation for their biological
effects.
drug metabolism  trimethylaminuria  oxygen
Two effective families of enzyme systems have evolved ineukaryotes to oxygenate xenobiotics: cytochromes P450 and
flavin-containing monooxygenases (FMOs). They both help
organisms to deal with potentially toxic exogenous compounds
from natural sources and, most notably in humans, represent the
enzyme systems involved in the metabolism of drugs and pol-
lutants (1). FMOs belong to the flavoenzyme class of single-
component flavoprotein monooxygenases (2); they use equiva-
lents from NADPH to reduce the FAD cofactor, which, in turn,
becomes capable of reacting with molecular oxygen to yield the
C4a-hydroperoxyFAD intermediate (Fig. 1A). This intermediate
is responsible of the insertion of one oxygen atom into a
substrate, with the production of the second intermediate C4a-
hydroxyFAD. The loss of the second oxygen atom from the
flavin in the form of a molecule of water restores the oxidized
cofactor (3). The first FMO isolated from pig liver was described
as liver microsomal FAD-containing monooxygenase (4) and
thoroughly characterized in its kinetic properties (5–8). FMOs
act on a variety of nonpolar substrates that contain soft nucleo-
phile heteroatoms (9). The most remarkable feature of their
catalytic cycle is their ability to stabilize the crucial C4a-
hydroperoxyFAD intermediate until a substrate gains access to
the active site (10). A prominent aspect is that the presence of
NADP is essential for intermediate stabilization and, consis-
tently, NADP remains bound to the enzyme throughout the
catalytic cycle, being the last product to be released (Fig. 1A) (6).
The human FMO (hFMO) gene family comprises five genes
and some pseudogenes. Of the five functional isoforms, hFMO3
is the one most abundantly expressed in adult liver and largely
involved in drug metabolism (11, 12). All isoforms display60%
sequence identity, a moderate level of polymorphism (13–15),
and the presence of tissue- and age-specific splice variants (16).
Several mutations in hFMO3 have been reported to cause the
inheritable disease known as trimethylaminuria (TMAU) or
‘‘fish-odor syndrome,’’ because of accumulation of substrate
trimethylamine in body fluids (17). All mammalian FMOs have
a strong membrane association and poor water solubility (9), and
no structure of a mammalian FMO is currently available.
In recent years, several plant (18) and prokaryotic enzymes
have been annotated as FMOs. The first discovered bacterial
FMO was identified in the methylotrophic bacterium Methyl-
ophaga sp. strain SK1 (mFMO) for the purpose of biocatalytic
production of the blue dye indigo (19). mFMO is not membrane-
associated. Its sequence (456 aa) scores 31% identity with
hFMO3 and contains two dinucleotide-binding signatures
(Rossmann folds) for FAD and NADP and the FMO-identifying
motif FXGXXXHXXX(Y/F) (20). mFMO shares 27% sequence
identity with Schizosaccharomyces pombe FMO, whose crystal
structure has been recently reported (21). The sequences of
Methylophaga, human, and S. pombe FMOs are aligned (22, 23)
in Fig. 1B.
Here, we present the biochemical characterization of mFMO
with kinetic data on a number of substrates and the 2.6-Å
resolution structure obtained by x-ray crystallography. In addi-
tion to the interest raised by the homology with the hFMOs, the
crystal structure of the bacterial enzyme highlights the direct
involvement of NADP in the stabilization of the crucial
C4a-hydroperoxyFAD intermediate, a unique feature of these
enzymes.
Results
Biochemical Properties. mFMO is a 2  53-kDa dimeric protein
containing one molecule of noncovalently tightly bound FAD
per monomer. The spectrum of the fully oxidized enzyme
exhibits typical maxima at 273, 372, and 442 nm, a shoulder at
462 nm, and a ratio Abs273/Abs442 of 9.9 (Fig. 2, trace A).
Addition of NADPH rapidly bleaches the protein solution,
accounting for an efficient reduction of the flavin cofactor. Like
commonly observed in mammalian enzymes (24), in the absence
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of an organic substrate, mFMO shows a slight NADPH oxidase
activity (Km,NADPH  13 M, kcat  0.06 s1 measured in
steady-state conditions) producing hydrogen peroxide (Fig. 1A).
The ability to stabilize the C4a-hydroperoxyflavin intermedi-
ate, well documented in the early works on pig FMO (4, 6, 7), can
also be demonstrated in mFMO. Mixing the enzyme with an
equimolar amount of aerated NADPH (in the absence of an
organic substrate) leads to the immediate formation of a C4a-
hydroperoxyflavin intermediate characterized by the typical
absorbance spectrum with a peak at360 nm (refs. 6, 25–27; Fig.
2, trace B). Over 30 min, the spectrum slowly reacquires the
characteristic 442-nm peak of the oxidized flavin (Fig. 2, traces
C to G). Conversely, addition of excess substrate immediately
brings the spectrum back to that of the fully oxidized flavin.
Steady-state kinetic assays performed at a fixed concentration
of NADPH with typical FMO substrates showed Michaelis–
Menten behavior (Table 1). Substrates were selected on the basis
of the following considerations: trimethylamine is a common
endogenous substrate for hFMO3; methimazole and (S)-(-)-
nicotine are of pharmacological relevance (9); methimazole and
N,N-dimethylaniline has been extensively exploited to test mam-
malian FMO activity in literature; indole is the putative substrate
of mFMO in the pathway for the production of indigo (19). All
these compounds are good substrates, with trimethylamine
exhibiting the highest catalytic efficiency (Table 1). An enzy-
matic activity has also been unexpectedly appreciated on di-
methyl sulfoxide initially used for dissolving some substrates,
confirming that mFMO accepts a broad range of N- and
S-containingmolecules largely overlapping with the substrates of
the first Rossmann fold for FAD binding, the fingerprint sequence for FMOs
(20), and the second Rossmann fold for NADP binding, respectively. The green
asterisks mark residues that are part of the active site, whereas the red
asterisks indicate residues that are mutated in patients affected by TMAU. The
alignment was performed with ClustalW2 (22) and ESPript (23).
Fig. 1. Biochemical properties of FMOs. (A) Scheme of the catalytic cycle.
NADP that forms upon reduction of the flavin cofactor stays bound through-
out the reaction and is essential for stabilization of C4a-hydroperoxyFAD
(Bottom Right) (3–6). Enzyme-bound NADP prevents FMO from working as
an NADPH oxidase, which would produce H2O2 (dashed line). S and S-O
indicate substrate and monooxygenated product, respectively. (B) Alignment
of the sequences of Methylophaga FMO (MeFMO), Homo sapiens FMO3
isoform 1 (hFMO3), and S. pombe FMO (SpFMO). Sequence identities to
hFMO3 are 31% for mFMO and 27% for S. pombe FMO. The red bars indicate
Fig. 2. Absorbance spectra of mFMO. Trace A represents the fully oxidized
form in the absence of NADP. Trace B was obtained as described in Materials
and Methods by the addition of an equimolar amount of NADPH under
aerobic conditions and is consistent with formation of the C4a-hydroperoxy-
flavin intermediate. The presence of a small amount of oxidized enzyme
because of the intrinsic NADPH-oxidase activity accounts for the shoulder
observed at 450 nm. Traces C to G were sequentially recorded after 25 sec,
90 sec, 3 min, 10 min, and 18 min and show the slow decay of the C4a-
hydroperoxyflavin intermediate, which is completed after 30 min.








mammalian FMOs. Moreover, as observed in steady-state ki-
netics of mammalian enzymes (4), NADP was competitive (Ki
of 30 M) with NADPH. Taken together, these observations
suggest that, similar to the mammalian FMOs, the bacterial
enzyme behaves like a ‘‘cocked gun,’’ spending most of the time
in the form of the hydroperoxyflavin intermediate. Any het-
eroatom-containing compound gaining access to the stabilized
intermediate is monooxygenated, in accordance with the striking
substrate promiscuity of FMOs.
Overall Three-Dimensional Structure. Wild-type mFMO crystal-
lized readily, but all crystals invariably suffered from severe
twinning. This problem was addressed by exploiting a number of
techniques, among which surface mutagenesis proved to be
successful (28). We targeted sets of two/three consecutive
charged residues (mainly Glu and Lys) supposed to be solvent-
exposed based on alignment with homologous proteins [sup-
porting information (SI) Table S1]. The mutant E158A/E159A
gave crystals that turned out to be free from twinning (the
mutant has biochemical properties virtually identical to those of
wild type; Table 1). Addition of NADP was essential for crystal
growth. mFMO structure was solved by single-wavelength anom-
alous dispersion method at 2.6-Å resolution (Tables 2 and 3) (29,
30). Protein molecules are arranged to give two identical ho-
modimers (Fig. 3) in the asymmetric unit, which is consistent
with the dimeric form determined by size-exclusion chromatog-
raphy for both wild-type and E158A/E159A mFMOs. However,
each of the active sites is exclusively built up by residues
belonging to a single subunit. rmsd between equivalent C atoms
of the monomers are 0.1 Å.
The protein is made up of two distinct domains (Fig. 3A), a
larger FAD-binding domain (residues 1–169 and 281–461) and
a smaller NADP-binding domain (residues 170–280). Both
domains display a typical dinucleotide-binding fold and are
connected through a double linker (around residues 170 and
280) that may act as a flexible hinge (Fig. 3A). There are three
long stretches interposed between the two domains; they lack
secondary structure elements (residues 44–80, 166–186, 276–
306), suggesting the absence of any rigid block opposing the
reciprocal movement of the domains. A relatively similar overall
conformation (rmsd of 2.3 Å for 343 C atoms) has been
observed in the structure of S. pombe FMO in complex with
NADP (21).
The Active Site. Inspection of the active site reveals the existence of
a cleft leading to theNADPmolecule at the interface between the
two protein domains (Fig. 4A). NADP occupies the cleft, blocking
the access to the flavin and the catalytic core. The nicotinamide ring
is sandwiched between the re side of the flavin and the single-helix
of theNADP-binding domain and is roughly coplanar with isoallox-
azine at a distance of 3.0–4.0 Å. Importantly, the nicotinamide
orients its reactive C4 away from the flavin N5 (C4-N5 distance of
5.1 Å) so that the NADP amide group is within hydrogen-bond
distances from the flavin O4 and N5. These potential hydrogen-
bond interactions led us to tentatively assign the orientation of the
NADP carboxamide group as shown in Fig. 4B. Spanning in
proximity of the flavin ring, a 161-Å3 cavity was detected by the
program VOIDOO (31) by using a 1.4-Å radius sphere as probe
(Fig. 4C). Its limits are defined by the isoalloxazine, the NADP
ribose and several protein residues (Asn-78, Gly-79, Pro-80, Cys-83,
Leu-84, Phe-402, Trp-405, Gln-323, Trp-324, Tyr-325, Ser-326,
Tyr-212). The role of Tyr-212 is remarkable, because its side chain
together with the ribose of NADP shields the cavity from the
outside, forming the only barrier to the solvent (Fig. 4).
After obtaining the native dataset at 2.6-Å resolution, several
attempts were made to bind substrate molecules inside the
crystals by either soaking or cocrystallization but none of them
were successful. Nevertheless, in the electron density map cal-
culated from soaked crystals (we refer to the experiment with
N,N-dimethylaniline hereafter named ‘‘dataset from soaking;’’
Tables 2 and 3), a well defined ellipsoidal peak of density was
found in proximity to the catalytic site inside the above-described
cavity, halfway between Tyr-212 and the pyrimidine ring of the
flavin (Fig. 4C). Alternative refinements with several candidate
molecules and atoms only yielded reasonable B-factors when
dioxygen or monoatomic ions of comparable electron density
were fitted inside. Based on these observations, we assigned the
orphan electron densities to dioxygen, which is included in the
coordinate file deposited in the Protein Data Bank (32). How-
ever, we do not rule out that, instead of molecular oxygen, a
superoxide molecule, possibly generated upon the x-ray expo-
sure of the crystal, is bound at this position. Likewise, the
presence of a monoatomic ion (especially if positively charged,
Table 1. Data from steady-state kinetic assays on mFMO
Substrate Km, M kcat, s1 kcat/Km, M1 s1
Trimethylamine 7.3  0.6 6.1  0.1 8.4  105  0.7
Trimethylamine
(E158A/E159A)
7.1  1 6.4  0.3 9.0  105  1
Nicotine 130  30 3.0  0.2 2.3  104  0.6
Methimazole 66  7 1.0  0.02 1.5  104  0.2
N,N dimethylaniline 232  28 1.8  0.4 7.8  103  2
Indole 90  14 0.7  0.03 7.8  103  1
Table 2. Data collection statistics
SeMet* Native Soaking†
a, c Å‡ 219.2, 126.7 219.6, 133.6 218.7, 130.7
Resolution, Å 3.0 2.6 2.8
Rsym§¶ 0.12 (0.51) 0.12 (0.45) 0.08 (0.43)
Completeness, %¶ 99.0 (97.2) 97.3 (86.1) 99.7 (100.0)
Redundancy¶ 5.1 (5.0) 3.0 (2.4) 3.2 (3.1)
I/(I)¶ 11.7 (2.1) 8.0 (2.3) 13.1 (2.1)
Unique reflections 69,172 110,675 86,940
*Phasing was performed with the program SHARP (41). The overall figure of
merit for centric and acentric and reflections was 0.2 and 0.4, respectively.
†The dataset was measured from a crystal soaked for 30 min at 4°C in a solution
containing N,N-dimethylaniline 5 mM, NADP 1 mM, PEG4000 25%(wt/vol),
Na/Hepes 0.1 M, pH 7.5.
‡The crystals were obtained with the mutant E158A/E159A. They belong to
space group P61, and their asymmetric unit contains four mFMO monomers.
§Rsymh i I(hkl)I(hkl)	 /h iI(hkl).
¶Data for the highest-resolution shell are given in parentheses.
Table 3. Refinement statistics
Native Soaking
Resolution, Å 2.6 2.8
R factor (Rfree)* 0.248 (0.269) 0.225 (0.242)
No. of protein atoms† 14,569 14,552
No. of water molecules 124 0
No. of FAD and NADP atoms 404 404
rmsd bond length, Å‡ 0.012 0.012
rmsd bond angle, °‡ 1.42 1.43
Ramachandran plot§
Most favorable region, % 89.2 88.2
Disallowed regions, % 0.0 0.0
*RfactorFobs  Fcalc/ Fobs .Rfree is theRfactor value for 5% of the reflections
excluded from the refinement.
†No electron density has been detected for residues 1–7 and 451–461.
‡rmsd from ideal values calculated with REFMAC5 (29).
§Figures from PROCHECK (30).
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such as K) cannot be excluded. A structural superposition of the
two sets of atomic coordinates (native dataset and dataset from
soaking) reveals that the accommodation of putative dioxygen
does not induce any significant shift in the position of protein
residues and cofactors.
Location of hFMO3 Mutations and Polymorphisms. The remarkable
degree of sequence identity makes it interesting to locate mFMO
residues corresponding to hFMO3 positions affected by patho-
logical mutations and polymorphisms (11, 17). All classical
TMAU-causing mutations target residues that are located either
in the active site or in structurally relevant regions (Figs. 1B and
3A). Examples are the human mutation Asn61Ser that targets
the catalytically crucial Asn-78 in mFMO and the Pro153Leu
mutation (homologous to mFMO Pro-173) that targets a residue
of the domain linker. Conversely, hFMO3 polymorphisms com-
monly observed in human populations concern positions that in
mFMO structure fall in solvent-exposed areas far apart from the
active site (Fig. 3A).
Discussion
We investigated mFMO for its ability to work as a good model
for the study of human enzymes. Biochemical analysis revealed
that this prokaryotic enzyme shares many functional properties
with mammalian FMOs, including the ability to stabilize C4a-
hydroperoxyFAD for minutes. The well known role of NADPH
coenzyme in the catalytic cycle of FMOs is that of providing
FAD with reducing equivalents (Fig. 1A). The chemistry of
NADPH requires that reduction of the flavin cofactor is brought
about through a hydride transfer from the C4 atom of the
nicotinamide ring to the flavin N5 atom (Fig. 4B). The stereo-
chemistry observed in mFMO structure does not reveal a close
proximity between these two crucial atoms and thus is clearly not
compatible with a hydride transfer. This implies that the struc-
ture in the crystals does not correspond to the conformation in
which NADPH is able to reduce the flavin. A modeling exper-
iment (Fig. 5A) in which the hypothetical coordinates of the
C4a-hydroperoxyflavin are superimposed onto the flavin coor-
dinates of the mFMO structure places the two additional oxygen
atoms of the C4a-adduct within hydrogen-bond distance from
O2
 atom of NADP ribose, which then would be perfectly
positioned to properly stabilize this oxygenating intermediate.
The positioning of the two additional oxygens would require only
a small (1–2 Å) shift of the Asn-78 side chain, which in turn could
contribute to their stabilization through polar interactions. Con-
sistently, the homologous Asn-61 of hFMO3 is essential for
activity (refs. 11 and 17; Fig. 3A). These considerations suggest
that the conformation in mFMO crystals is likely to correspond
to that promoting the stabilization of C4a-hydroperoxyFAD.
This feature is known to depend on the presence of NADP that
was proposed to act as a ‘‘gate keeper,’’ preventing the decay of
the intermediate possibly by protecting the flavin N5 from
solvent attack (6). Our structure helps to explain these functional
properties and is a clear observation of a second fascinating
functional property of NADP in FMO catalytic cycle, i.e., the
stabilization of C4a-hydroperoxyflavin. NADP shields the ac-
tive site and provides a proper H-bonding environment that can
prolong the intermediate half-life. Therefore, NADP is an
integral part of the enzyme catalytic machinery that promotes
intermediate stabilization and substrate monooxygenation. The
approach of a substrate to the intermediate may be promoted by
a displacement of both the loop of Tyr-212 (NADP-binding
domain) and the stretch of residues 407–415 at the end of a
-helix (FAD-binding domain, Fig. 3A), as suggested by the
higher B-factors of this protein region.
The crystal structure of mFMO is similar to that of S. pombe
FMO (21). In particular, most of the catalytic residues are
identical in the two enzymes (Fig. 1B), which display similar
active sites and, most importantly, essentially the same confor-
mation of bound NADP (Fig. 5B). In their original article,
Eswaramoorthy et al. (21) explained the observed NADP-
binding mode as indicative of a flavin-reduction mechanism
involving hydride transfer from the nicotinamide C2 atom
(rather than C4) to the flavin. This interpretation has been
subsequently revised as not compatible with known NADP(H)
chemistry without any further comment (33). We believe that, in
view of their structural similarity, Methylophaga and S. pombe
FMOs are very likely to have a similar catalytic mechanism with
NADP being actively involved in the stabilization of the
C4a-hydroperoxyflavin intermediate as described above. In this
context, we remark that also sequence-related Baeyer–Villiger
monooxygenases, e.g., cyclohexanone monooxygenase and phe-
nylacetone monooxygenase (34, 35), probably use the same
catalytic strategy. Indeed, for phenylacetone monooxygenase it
has been shown that NADP is a prerequisite for efficient and
Fig. 3. Overall crystal structure of mFMO. (A) Ribbon diagram of the
monomer. FAD-binding domain (residues 8–169 and 281–450) is orange and
NADP-binding domain (residues 170–280) is green. FAD is shown as yellow
sticks and NADP as blue sticks. The positions of the long interdomain loop
(residues 44–80), the hinge connecting the two domains, and the polypeptide
stretch corresponding to residues 407–415 are outlined. mFMO residues
corresponding to TMAU-causing mutations (17) and polymorphisms in hFMO3
(in parentheses) are in red and blue sticks, respectively. The position of a long
insert in hFMO3 (residues 238–299; Fig. 1B) is also indicated. It is expected to
occupy a surface-exposed position away from the active site. (B) Ribbon
representation of the mFMO dimer. One monomer is shown in the same
orientation and color as Fig. 3A; the other one is colored gray, with the
NADP-binding domain in darker gray.








enantioselective catalysis (36) and its crystal structure predicts a
NADP-binding mode identical to that found in FMOs, sug-
gesting a similar mechanism of intermediate stabilization (37).
To bring about the first of its two roles (reduction of FAD by
hydride transfer; Fig. 1A), NADPH coenzyme must occupy a
position different from that observed in our structure. A shift of
the ribose ring of NADP coenzyme might be enough to move
the nicotinamide ring to a position productive for hydride
transfer. However, our repeated observation that soaking
mFMO crystals in a solution of fresh NADPH rapidly bleaches
and cracks them rather suggests that a relative domain rotation
could be involved in promoting FAD reduction by NADPH. A
similar movement has been hypothesized for proteins with
similar topology (38) and in the catalytic mechanism of pheny-
lacetone monooxygenase (37).
In conclusion, in FMOs and related monooxygenases,
NADP(H) has two binding modes likely to be associated to
distinct protein conformational states; the first binding mode
along the catalytic cycle promotes FAD reduction through
hydride transfer, whereas the secondmode exerts stabilization of
the crucial catalytic intermediate, a sort of moonlighting activity
of NADP(H).
Materials and Methods
Crystallization and Structure Determination. Gene cloning and protein expres-
sion and purification were carried out by using standard protocols as de-
scribed in SI Text. Wild-type mFMO crystallized in many conditions using
low-molecular-weight PEGs as precipitant. However, these crystals were af-
fected by twinning. Conversely, mutant FMO E158A/E159A (SI Text) gave
crystals of a different form in microbatch technique at 4°C by mixing equal
volumes of 8 mg of protein/ml in TrisHCl 25 mM, pH 8.0; NaCl 250 mM; NADP
1 mM and of PEG4000 20% (wt/vol) in Na/Hepes 0.1 M, pH 7.5. These crystals
were not affected by twinning and could be used for structure determination.
Data were collected at the European Synchrotron Radiation Facility
(Grenoble, France) and processed with the CCP4 package (39). The structure
was solved by the single-wavelength anomalous diffraction method (Table 2)
by using SHELXD (40) and SHARP (41). The resulting electron density map was
Fig. 4. The active site of mFMO. (A) Surface representation of the enzyme with the catalytic site viewed from outside using the coloring scheme and
approximately the same orientation of Fig. 3B. (B) Binding of the NADP nicotinamide ring. Only crucial residues are displayed. Oxygen is red, nitrogen is blue,
carbon is differently colored depending on its belonging to FAD (yellow), NADP (cyan), FAD-binding domain (orange), NADP-binding domain (green). For the
sake of clarity, only the backbone atoms of Trp-76 are shown. The reactive C4a and N5 atoms of the flavin and C4 of NADP nicotinamide are labeled. (C)
Stereoscopic view of the active site of mFMO in approximately the same orientation as Fig. 4B and with the same color code. The red-colored electron density
(2FoFc, contoured at 1.5 ) was found in the dataset resulting from a soaking experiment (Table 2) and tentatively assigned to a dioxygen bound inside the
cavity located in front of the flavin (here shown as a light blue transparent surface).
Fig. 5. The role of NADP in the stabilization of C4a-hydroperoxyflavin
intermediate. (A) Modeling experiment in which the hypothetical structure of
C4a-hydroperoxyflavin was superimposed to the flavin in mFMO structure.
The color code is the same as in Fig. 4B. Hypothetical hydrogen bonds involving
the hydroperoxyflavin atoms are shown as blue dashed lines. The accommo-
dation of the additional oxygen atoms of the C4a-adduct would require a shift
of1.5 Å of Asn-78 side chain (whose conformation in the native structure is
shown as thin black stick). (B) Comparison of the NADP-binding mode in S.
pombe (Protein Data Bank ID code 2gv8) and Methylophaga FMOs. The
picture was obtained by superimposing the C atoms of the two proteins and
shows the FAD (yellow) and NADP (blue) molecules of mFMO together with
FAD and NADP of the S. pombe enzyme (red). The N5 and C4a atoms of the
flavin and C4 and C2 atoms of NADP are labeled.
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used in molecular replacement calculations to solve the structure of the native
(nonselenomethionine-substituted) enzyme. Phases were further improved
by multiple-crystal density averaging with DMMULTI (39). All subsequent
model-building and refinement calculations were done by using data from
the native crystals. The initial model was traced with ARP/wARP (42). The
programs COOT (43) and Refmac5 (29) were used for model rebuilding and
refinement (Table 3). Figures were generated by using PyMOL (DeLano Sci-
entific; www.pymol.org).
Kinetic Assays. Kinetic assays were performed in duplicate at 25°C on a Varian
spectrophotometer (Cary 100 Bio) equipped with a thermostatic cell compart-
ment. A 1-ml mixture containing mFMO 0.1–0.2 M; TrisHCl 25 mM, pH 8.5;
NaCl 35 mM; 0.1 mM NADPH (dissolved in NaOH 20 mM) was equilibrated for
2 min; the reaction was triggered by addition of substrate and followed by
decrease in absorbance at 340 nm (340  6.22 mM1 cm1 for NADPH). All
substrates (Table 1) were dissolved in water except N,N-dimethylaniline (dis-
solved in ethanol). Km for NADPH was measured by using a fixed trimethyl-
amine concentration (2 mM) and varying NADPH concentrations (0–230 M).
To generate the C4a-hydroperoxyflavin intermediate (Fig. 2, trace B), an
aerated solution of NADPH 7 M was added to a solution of mFMO (7 M in
KPi 100 mM, pH 7.4) in a final volume of 1 ml at 4°C.
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